AFM
AUPH icon

Anson Funds Management’s Aurinia Pharmaceuticals AUPH Stock Holding History

Anson Funds Management’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-29,900
Closed -$250K – 49
2017
Q1 		$250K Sell
29,900
-358,108
-92% -$1.65M 0.1% 40
2016
Q4 		$815K Buy
+388,008
New +$1.25M 0.25% 37

Other funds holding AUPH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Anson Funds Management's AUPH Position: Q2 2017 in Review

Anson Funds Management sold out of Aurinia Pharmaceuticals (AUPH) in Q2 2017, closing a stake of 29,900 shares — an estimated $250K sold.

Anson Funds Management first reported a position in AUPH in Q4 2016 and held it in 2 quarters. The position peaked at $815K in Q4 2016. 65 funds tracked by Wall St. Rank hold AUPH as of Q2 2017.

  • Anson Funds Management reported no remaining Aurinia Pharmaceuticals position as of Q2 2017 after selling out during the quarter.
  • Anson Funds Management sold 29,900 Aurinia Pharmaceuticals shares in Q2 2017, an estimated $250K.
  • Anson Funds Management first reported a position in Aurinia Pharmaceuticals in Q4 2016 and held it in 2 quarters.
  • Anson Funds Management's Aurinia Pharmaceuticals position peaked at $815K in Q4 2016.
  • 65 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q2 2017.

Based on Anson Funds Management's 13F filing for Q2 2017, filed 14 Aug 2017.